Screening Pfizer Compounds for Antimalarial Drug Discovery

On going
Start date
Start stage
Research areas

In 2019, malaria caused an estimated 229 million clinical episodes and 409,000 deaths. As development of resistance to existing drugs is one of the greatest threats to malaria control, it is critical that new potential therapeutics be developed. Dr. Tomoyoshi Nozaki, Professor at the Graduate School of Medicine, University of Tokyo, is working toward the discovery and development of novel potential treatments for malaria. To support Dr. Nozaki’s drug discovery research, Pfizer Inc. has agreed to provide certain compounds that may inhibit selected targets.